Cibc World Market Inc. Takes Position in Edwards Lifesciences Corporation $EW

Cibc World Market Inc. bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 39,743 shares of the medical research company’s stock, valued at approximately $3,595,000.

Several other large investors have also recently bought and sold shares of EW. Hanson & Doremus Investment Management bought a new position in shares of Edwards Lifesciences during the 1st quarter worth about $25,000. JPL Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the third quarter valued at about $25,000. MV Capital Management Inc. bought a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $26,000. RMG Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the first quarter valued at about $26,000. Finally, TrinityBridge Ltd acquired a new stake in Edwards Lifesciences during the second quarter worth about $27,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $90.93 on Thursday. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $52.36 billion, a PE ratio of 52.26, a price-to-earnings-growth ratio of 2.38 and a beta of 0.85. The firm has a 50-day moving average price of $89.43 and a 200 day moving average price of $84.91.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. During the same quarter last year, the company earned $0.67 earnings per share. The company’s revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the sale, the vice president directly owned 40,034 shares in the company, valued at $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the transaction, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 2,425 shares of company stock valued at $219,199 in the last 90 days. 0.31% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Evercore reaffirmed an “outperform” rating and issued a $100.00 price target on shares of Edwards Lifesciences in a report on Monday, July 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Piper Sandler restated an “overweight” rating and set a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Wall Street Zen lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Finally, JPMorgan Chase & Co. raised their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Seventeen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $100.27.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.